Emerging factors affecting peri-implant bone metabolism.
Angel InsuaPablo Galindo-MorenoRichard J MironHom-Lay WangAlberto MonjePublished in: Periodontology 2000 (2023)
Implant dentistry has evolved to the point that standard implant osseointegration is predictable. This is attributed in part to the advancements in material sciences that have led toward improvements in implant surface technology and characteristics. Nonetheless, there remain several cases where implant therapy fails (specifically at early time points), most commonly attributed to factors affecting bone metabolism. Among these patients, smokers are known to have impaired bone metabolism and thus be subject to higher risks of early implant failure and/or late complications related to the stability of the peri-implant bone and mucosal tissues. Notably, however, emerging data have unveiled other critical factors affecting osseointegration, namely, those related to the metabolism of bone tissues. The aim of this review is to shed light on the effects of implant-related factors, like implant surface or titanium particle release; surgical-related factors, like osseodensification or implanted biomaterials; various drugs, like selective serotonin reuptake inhibitors, proton pump inhibitors, anti-hypertensives, nonsteroidal anti-inflammatory medication, and statins, and host-related factors, like smoking, diet, and metabolic syndrome on bone metabolism, and aseptic peri-implant bone loss. Despite the infectious nature of peri-implant biological complications, these factors must be surveyed for the effective prevention and management of peri-implantitis.
Keyphrases
- soft tissue
- bone loss
- bone mineral density
- metabolic syndrome
- bone regeneration
- end stage renal disease
- gene expression
- ejection fraction
- insulin resistance
- type diabetes
- healthcare
- anti inflammatory
- smoking cessation
- chronic kidney disease
- risk assessment
- emergency department
- stem cells
- climate change
- patient reported outcomes
- body composition
- machine learning
- drug induced
- replacement therapy